|
Press Release
BioTeam Names SGI, Mitrionics and Accelerated Blast in Top Ten Bio-It Trends for 2007 Mitrionics and Mitrion-Accelerated BLAST Named in #5 "Reconfigurable Accelerator Boards (FPGAs)" Along with SGI SUNNYVALE, Calif. and LOS ANGELES, Calif. (March 9, 2007) SGI (NASDAQ: SGIC), manufacturer of FPGA (Field Programmable Gate Array)-based SGI® Altix® family servers with SGI® RASC RC100 computation blades, and Mitrionics, Inc., developer of the Mitrion Virtual Processor and software-centric Mitrion-C programming language for FPGA Supercomputing acceleration, were named as one of the Top Ten BioIT Trends for 2007 that was published in the industry publication BioIT World. Compiled by the BioTeam, a consulting collective dedicated to delivering vendor-agnostic informatics solutions to the life sciences industry, Mitrionics and its close FPGA Supercomputing provider SGI were both named in the #5 Top BioIT Trend — "Reconfigurable Accelerator Boards (FPGAs)."The first thing I should mention is that the list is totally unordered, so being number 5 is not necessarily different than being 3 or being 8," said Christopher Dwan, BioTeam Principal Investigator, who recommended the addition of FPGAs to the BioIT Trends list. "Reconfigurable computing devices occupy this interesting ground between absolute standard CPUs and completely custom computing hardware. In a number of cases, they have been shown to deliver substantial improvements in performance, price/performance and power consumption." Additionally, the collaborative efforts of SGI and Mitrionics directly address the #1 Top Ten BioIT Trend for 2007 — which is "Power and Cooling Costs". SGI and Mitrionics are the leaders in the expanding market of FPGA Supercomputing — where applications are modified to be accelerated (10x to 100x) on computer systems utilizing FPGAs. Mitrionics has also accelerated the NCBI BLAST bioinformatics application and is delivering that as a turnkey solution worldwide with SGI. # 5 Top BioIT Trend for 2007 as described in the Dec/Jan 2007 Issue of BioIT World — Vol. 5, no. 10. "For about the past 6 or 7 years I've been going to the Supercomputing conference; I've seen reconfigurable devices like the FPGAs and they've been lacking two critical parts. One: they are more difficult to use than general processors because you have to put in a lot more effort to build out this custom thing to get essentially the same result, except that same result is going to be faster. FPGAs have been lacking either an easy way for its users to do that, or an established person in the middle who builds out the specific tool for the specific application area, at least in the life sciences. You want something that makes your science easier to do, not harder," said Dwan. "This year at Supercomputing ‘06, I saw several companies stepping into that gap, specifically Mitrionics, coming out with their compiler libraries and all sorts of expertise in various scientific domains," continued Dwan. "It strikes me as exactly what is needed in order to turn FPGAs from a potentially useful technology into something where, in a year, we're going to be saying ‘Wow! Why didn't anybody do that sooner?' "And the second factor that I saw is the partnership with major hardware vendors, and by hardware vendors I mean the people who, at the end of the day, sell hardware to customers," said Dwan. "Instead of vendors viewing this technology as a competition to their core chip business as in the past, SGI and some others are seeing it as a value-add that makes the product offering more powerful. People are going to buy a particular brand because of the support, because of the reliability, and also because the product is tightly integrated and partnered with these reconfigurable accelerator boards. I've been saying, "Wow, FPGAs are going to be the next big thing" forever. I think it's this year. It seems to me that Mitrionics and SGI finally see the two pieces that were missing in the stack. They finally got it. I think we're going to start seeing some really interesting products." #1 Top BioIT Trend for 2007 as described in the Dec/Jan 2007 Issue of BioIT World — Vol. 5, no. 10. "I think in terms of genomes analyzed per ton of coal," said Dwan, who was also instrumental in selecting "Power and Cooling Costs" for the Top Ten trends article. "If coal is used to generate electricity and the end goal is to analyze genomes, there's some exchange we're making between digging up dirty stuff out of the ground and getting useful scientific knowledge. I wrote a column in Bio IT World exclusively dedicated to power in the data center and what it costs. The number that I came up with was approximately $1 per day per server. That's not unreasonable for a human being sitting in their home with a computer: $365 a year to have this device on. But when you stack them up into, say, a 200-node cluster, that's $200 a day. Suddenly I've got about a full-time employee's worth of electricity being burned. And that's a recurring cost that's only going to get more expensive as electricity gets more expensive. Then, there are environmental concerns. It's going to be absolutely huge to say ‘Okay, can we be just a bit more efficient?' We have a choice between having one special-purpose device -- or we could do it with general-purpose processors, but it will take 20 times as many of them. If you're going to be doing scientific research, such as genomic data matching for typically two years, you can see the cost-savings immediately." "We believe our accelerated turnkey bioinformatics solutions, currently offered in conjunction with our close partner SGI, are going to dramatically increase the market adoption of real-world, FPGA-accelerated systems and applications in 2007. Customers from around the globe have shown strong interest in our Mitrion-accelerated BLAST, and we're following that up with additional BLAST versions, and other applications for bioinformatics," stated Anders Dellson, CEO of Mitrionics, Inc. "Mitrionics is also very involved in developing or co-developing FPGA-accelerated applications for a variety of industry segments as well as government and scientific projects. The success SGI and Mitrionics are having in FPGA Supercomputing really demonstrates what can be accomplished when you have two companies in the right places, at the right time, working together. After years of interest and hype about the ability of FPGA's to accelerate application performance, the next few months and quarters are going to transform what was previously just potential into a practical reality that will redefine this technology and market segment." "An FPGA draws one-quarter to one-third the power of a CPU, and yet can generate results more rapidly," said Michael Brown, sciences segment manager at SGI. "The combination of higher performance with lower power consumption will figure heavily in purchasing decisions in the sciences and other industries. Scientists are already using SGI RASC capabilities to effectively obtain results from the mountains of genomic data being generated by next generation genome sequencers." About Mitrion-Accelerated BLAST About BLAST About the Mitrion Platform and Mitrion Virtual Processor About Mitrionics About BioTeam SGI - Innovation for Results © 2006 SGI. All rights reserved. SGI, Altix, the SGI cube and the SGI logo are registered trademarks, and RASC is a trademark of SGI in the United States and/or other countries worldwide. Mitrionics, Mitrion, Mitrion Platform, Mitrion Virtual Processor, and Mitrion Software Development Kit are trademarks of Mitrionics, Inc. All other trademarks mentioned herein are the property of their respective owners. This news release contains forward-looking statements regarding SGI technologies and third-party technologies that are subject to risks and uncertainties. These risks and uncertainties could cause actual results to differ materially from those described in such statements. The reader is cautioned not to rely unduly on these forward-looking statements, which are not a guarantee of future or current performance. Such risks and uncertainties include long-term program commitments, the performance of third parties, the sustained performance of current and future products, financing risks, the ability to integrate and support a complex technology solution involving multiple providers and users, and other risks detailed from time to time in the company's most recent SEC reports, including its reports on Form 10-K and Form 10-Q. | |